Successful treatments with polymyxin B hemoperfusion and recombinant human thrombomodulin for fulminant *Clostridium difficile*-associated colitis with septic shock and disseminated intravascular coagulation: a case report

Kazuhito Minami1*, Yoshihisa Sakaguchi2, Daisuke Yoshida1, Manabu Yamamoto1, Masahiko Ikebe1, Masaru Morita1 and Yasushi Toh1

Abstract

**Background:** *Clostridium difficile* (CD)-associated colitis (CDAC) is endemic and a common nosocomial enteric disease encountered by surgeons in modern hospitals due to prophylactic or therapeutic antibiotic therapies. Currently, the incidence of fulminant CDAC, which readily causes septic shock followed by multiple organ dysfunction syndromes, is increasing. Fulminant CDAC requires surgeons to perform a prompt surgery, such as subtotal colectomy, to remove the septic source. It is known that fulminant CDAC is caused by the shift from an inflammatory response at a local mucosal level to a general systemic inflammatory reaction in which CD toxin-induced mediators’ cascades disseminate. Recently, it has been proven that polymyxin B hemoperfusion (PMX-HP) improves septic shock and recombinant human thrombomodulin (rhTM) controls disseminated intravascular coagulation (DIC). In addition, clinically and basically, it has been shown that these treatments can control serous chemical mediators. Therefore, it is considered that these treatments are promising ones for patients with fulminant CDAC. In the current report, we present that these treatments without surgery contributed to the improvement of sepsis due to fulminant CDAC.

**Case presentation:** We encountered a case who developed fulminant CDAC with septic shock and DIC after laparoscopic gastrectomy for gastric cancer. At admission to the intensive care unit, his APACHE II score was 22, which indicated an estimated risk of hospital death of 42.4%. Our therapies were not the subtotal colectomy to remove septic sources but the combination treatments with both PMX-HP and rhTM. These combination therapies resulted in excellent outcomes, namely the dramatic improvement of septic shock and DIC and the patient’s survival. We speculate that these combination therapies completely inhibit the CD toxin-induced mediators’ cascades and correspond to the removal of septic sources.

**Conclusions:** We recommend both PMX-HP and rhTM for patients who develop fulminant CDAC with septic shock and DIC to increase the survival benefit and replace the need for surgical treatment.

**Keywords:** Fulminant *Clostridium difficile*-associated colitis, Septic shock, Disseminated intravascular coagulation (DIC), Polymyxin B hemoperfusion (PMX-HP), Recombinant human thrombomodulin (rhTM)
Background

Clostridium difficile (CD)-associated colitis (CDAC), which is one of the common nosocomial enteric diseases encountered by surgeons, is typically due to the exposure of antibiotics and consequently endemic disease in modern hospitals [1–3]. Recently, the incidence of fulminant CDAC, which readily causes septic shock followed by multiple organ dysfunction syndromes (MODS), is increasing [4–7]. Fulminant CDAC often requires surgeons to perform a prompt invasive surgical treatment, such as a subtotal colectomy, in order to remove the septic source and improve the patient’s fatal situation [7–19].

Recently, it has been proven that polymyxin B hemoperfusion (PMX-HP) improves septic shock [20–23] and recombinant human thrombomodulin (rhTM) controls disseminated intravascular coagulation (DIC) [24–29]. In addition, clinically and basically it has been shown that these treatments can control serous chemical mediators. On the other hand, it is known that fulminant CDAC with MODS is caused by the shift from an inflammatory response at a local mucosal level to a general systemic inflammatory reaction in which CD toxin-induced mediators’ cascades disseminate [30–36]. Therefore, it is considered that these treatments are promising ones for patients with fulminant CDAC.

In the current report, we present that these treatments without surgery contributed to the improvement of sepsis due to fulminant CDAC.

Case presentation

A 51-year-old male patient who underwent laparoscopic partial gastrectomy for early gastric cancer had been given intravenous cefazolin for 2 days preventively and 5 days after the surgery suddenly developed a high-grade fever (over 39 °C) and severe diarrhea. We immediately administered oral vancomycin (VCM), Lac-B, viz. probiotics; and enough extracellular fluid because we empirically suspected that these symptoms were due to CDAC or methicillin-resistant Staphylococcus aureus-associated enteritis. A diagnosis of CDAC was rapidly made by confirming the presence of toxin A in his feces. Although these medications were initiated, 24 h after the onset the patient developed septic shock requiring vasopressor agents and MODS composed of DIC and acute renal failure (ARF). When he was transferred to the intensive care unit (ICU), his Acute Physiology and Chronic Health Evaluation II (APACHE) II score [37] was 22, which estimated his risk of hospital death to be 42.4 % (Table 1). According to the clinical and radiological findings, he did not have any colonic perforation or toxic megacolon; thus, we avoided an invasive surgery (such as subtotal colectomy) but alternatively treated him using both PMX-HP to improve septic shock [20–23] and rhTM to control DIC [24–29]. In the first 6 h after starting both treatments, his systolic blood pressure (SBP) improved, requirement for the vasopressor agent decreased, and body temperature (BT) dropped by approximately two degrees. Twenty-four hours after the treatments, septic shock was dramatically improved (Fig. 1). Three days after the treatments, an improvement in severe inflammation was noted according to white blood cell (WBC) count and C-reactive protein (CRP) level (Fig. 2) and an improvement in DIC according to the fibrin degradation product (FDP) level and prothrombin time (PT) (Fig. 3). A temporary decline in the platelet count was controllable with platelet transfusion (Fig. 3). Although four cycles of continuous hemodiafiltration (CHDF) were necessary as a replacement therapy to ARF, the further progression of MODS was not

### Table 1 Vital signs, APACHE II score, and laboratory data at the time of ICU transfer

| Test                        | Value          |
|-----------------------------|----------------|
| Body temperature (°C)       | 40             |
| Symbolic blood pressure (mmHg) | 80             |
| Median blood pressure (mmHg) | 43             |
| Administration of dopamine (μG) | 10            |
| Heart rate (bpm)            | 150            |
| Respiratory rate (bpm)      | 32             |
| Urine output (ml/h)         | 5              |
| Glasgow coma scale          | 15             |
| Estimated risk of hospital death (%) | 42.4 |
| CRP (mg/dl)                 | 24.2           |
| APACHE II score             | 22             |
| PT (%)                      | 55             |
| Estimated risk of hospital death (%) | 42.4 |
| FDP (µg/ml)                 | 36.5           |
| pH                          | 7.38           |
| PaO₂/FiO₂ (mmHg)            | 322            |

**Abbreviations:** APACHE II Acute Physiology and Chronic Health Evaluation II, Ht hematocrit, WBC white blood cell, PLT platelet, T. bil total bilirubin, Na serum sodium, X serum potassium, Scr serum creatinine, CRP C-reactive protein, PT prothrombin time, FDP fibrin degradation products, pH hydrogen ion concentration, PaO₂ airway opening pressure, FiO₂ fraction of inspired oxygen

**Fig. 1** Clinical course of the vital signs and treatments. Abbreviations: SBP systolic blood pressure, BT body temperature, DOP dopamine, PMX-HP polymyxin B hemoperfusion, rhTM recombinant human thrombomodulin
observed and the APACHE II score satisfactorily decreased daily (Fig. 4). Although clinically moderate diarrhea and a mild fever were observed, his general condition also improved. Consecutive toxin A tests, except the first one, were all negative. Five days after the treatments, the patient overcame fulminant CDAC through the use of the abovementioned therapies. Throughout the entire clinical course, neither endotoxemia nor bacteremia was observed.

Discussion
Currently, CDAC is endemic and a common nosocomial enteric disease encountered by surgeons in modern hospitals due to prophylactic or therapeutic antibiotic therapies [1–3]. Recently, both the incidence and the severity of CDAC have been increasing, and one possible explanation for these increases is the emergence of highly toxigenic and lethal strains of CD [4–7]. The above shows the need for surgeons to consider more serious treatment against CDAC. In fulminant CDAC, which has a higher lethal rate, it is especially necessary for surgeons to promptly decide whether or not to perform an invasive surgical treatment, such as subtotal colectomy, which means the removal of the septic sources and probable improvement of the patients’ ill condition [7–19].

In our case that suddenly developed fulminant CDAC with septic shock requiring vasopressor agents and MODS composed of DIC and ARF, prompt surgical treatment in order to remove the septic sources was recommended. However, we alternatively treated the patient with both PMX-HP and rhTM therapies. The reason for having chosen these treatments is as follows: (1) there was neither colonic perforation nor toxic megacolon, which absolutely requires surgery; (2) PMX-HP is an effective extracorporeal blood purification treatment for improving septic shock [22]; and (3) rhTM can effectively inhibit systemic dissemination of intravascular coagulation [24–29]. The combination therapies produced excellent outcomes in this case, namely the dramatic improvement of septic shock and DIC, the inhibition of MODS progression, and the patient’s survival. We speculate that the two below-mentioned factors corresponded to the removal of the septic source, namely as result of the surgical treatment. First, oral VCM medication could suppress CD’s proliferation and the further production of CD toxins. Second, both PMX-HP and rhTM could completely inhibit the CD toxin-induced mediators’ cascades. This notion is based on the following evidence. First, fulminant CDAC with MODS is caused by the shift from an inflammatory response at a
local mucosal level to a general systemic inflammatory reaction in which CD toxin-induced mediators’ cascades disseminate [30–36]. Second, although PMX-HP removes circulating endotoxin by adsorption and theoretically prevents the progression of the biochemical cascade of sepsis, several studies and published reports have demonstrated that PMX-HP can reduce the plasma levels of cytokines and sepsis-related factors, namely TNF-α, IL-6, IL-10, N-arachidonoylethanolamine (AEA), 2-arachidonoyl glycerol (2-AG), and high-mobility group box-1 (HMGB-1) [21, 23, 38, 39]. Indeed, there were case reports published which showed that PMX-HP decreases the serum levels of endogenous cannabinoids (anandamide and 2-AG) and inflammatory cytokine (IL-6) in parallel with the clinical improvement of fulminant CDAC [40, 41]. Third, many studies and fundamental researches have shown that rhTM also has an anti-inflammatory ability through both the activated protein C and the lectin-like domain-dependent pathway [42–46]. In particular, the thrombin-rhTM complex demonstrates an anti-inflammatory ability through neutralizing HMGB-1 [47, 48], which is known to be a mediator of lethality and is released from necrotic cells or macrophages/activated dendritic cells with potent pro-inflammatory function, which in turn causes shock or MODS when being disseminated in the systemic circulation [49–51]. Finally, septic shock and MODS in our case were not induced by endotoxia or bacteremia, and a dramatic improvement was observed immediately after the initiation of the combination therapies.

Conclusions
Both PMX-HP and rhTM therapies for patients who develop fulminant CDAC with septic shock and DIC can provide survival benefits and replace the need for invasive surgical treatments to remove the septic sources.

Consent
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations
APACHE II; Acute Physiology and Chronic Health Evaluation II; BT, body temperature; CD, Clostridium difficile; CDAC, Clostridium difficile-associated colitis; CHDF, continuous hemodiafiltration; CRP, C-reactive protein; DIC, disseminated intravascular coagulation; FDP, fibrin degradation product; MODS, multiple organ dysfunction syndromes; PMX-HP, polymyxin B hemoperfusion; rhTM, recombinant human thrombomodulin; SBP, systolic blood pressure; VCM, vancomycin; WBC, white blood cell

Acknowledgements
The authors thank Dr. Brian Quinn for the assistance in editing the manuscript.

Authors’ contributions
SY contributed in writing the paper and supervised the study. YD, YM, and IM supervised the study. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Gastroenterological Surgery, National Kyushu Cancer Center, Notame 3–1–1, Minami-ku, Fukuoka 811–1395, Japan. 2Department of Gastroenterological Surgery, National Hospital Organization Kyushu Medical Center, Jigyohama 1–8–1, Chuo-ku, Fukuoka 810–8563, Japan.

Received: 13 May 2016 Accepted: 1 July 2016
Published online: 28 July 2016

References
1. McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204–10.
2. Gerding DN, Johnson S, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995;16:459–77.
3. Wiesen P, Van Gossum A, Preiser JC. Diarrhoea in the critically ill. Curr Opin Crit Care. 2006;12:149–54.
4. Pepin J, Valliquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466–72.
5. Wann Y, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079–84.
6. Chernak E, Johnson CC, Welman A, Wiggs L, Kligore G, Thompson A, LeMalle-Williams M, Tan E, Lewis FM. Severe Clostridium difficile-associated disease in populations previously at low risk—four states, 2005. MMWR Morb Mortal Wkly Rep. 2005;54(47):1201–1205.
7. Lamontagne F, Labbe AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg. 2007;171:47–8.
8. Synnott K, Mealy K, Merry C, et al. Timing of surgery for fulminant pseudomembranous colitis. Br J Surg. 1998;85:229–31.
9. Dallal RM, Harbrecht BG, Boupoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235:363–72.
10. Longo WE, Mazuski JE, Virgo KS, et al. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum. 2004;47:1620–6.
11. Koss K, Clark MA, Sanders DS, et al. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis. 2006;8:149–54.
12. Byn JC, Maun DC, Gingold DS, et al. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg. 2008;143:150–4.
13. Ali SO, Weich JP, Dring RJ. Early surgical intervention for fulminant pseudomembranous colitis. Ann Surg. 2008;74:20–6.
14. Sailhamer EA, Carson K, Chang Y, et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg. 2009;144:433–9.
15. Christopher WS, Mario RY, James R, et al. Early colectomy may be associated with improved survival in fulminant Clostridium difficile colitis: an 8-year experience. Ann J Surg. 2009;197:302–7.
16. Parag B, Celia MD. Surgical aspects of fulminant Clostridium difficile Colitis. Am J Surg. 2010;200:131–5.
17. Osman KA, Ahmed MH, Hamad MA, et al. Emergency colectomy for fulminant Clostridium difficile colitis: striking the right balance. Scand J Gastroenterol. 2011;46:1222–7.
18. Bhangu A, Nopogodiev D, Gupta A, et al. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg. 2012;99:1501–13.
19. Andrew JK, Alexey M. Current status of surgical treatment for fulminant Clostridium difficile colitis. World J Gastroenterol. 2013;5(6):167–72.
20. Cruz DN, Peszea MA, Bellomo R, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systemic review. Crit Care. 2007;11:847.
21. Shimizu T, Hanasawa K, Sato K, et al. The clinical significance of serum procalcitonin levels following direct hemoperfusion with polymyxin B-immobilized fiber column in septic patients with colorectal perforation. Eur Surg. 2009;42:109–17.
et al. Surgical Case Reports (2016) 2:76

High-mobility group box 1 colitis during an *Clostridium difficile* toxin A and toxin B. Infect Immun. 1991;59(5):3659–66.

24. Nakamura K, Fujiwara M, Mohri T, et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care. 2011;15:R123.

25. Aikawa N, Shimazaki S, Yamamoto Y, et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. SHOCK. 2011;35(4):349–54.

26. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417–20.

27. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5(1):31–41.

28. Yamanaka K, Fujimi S, Mohri T, et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care. 2011;15:R123.

29. Nakamura K, Fujiwara M, Mohri T, et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care. 2011;15:R123.

30. Cunney R, Magee C, McNamara E, et al. Immunomodulatory activities of surface-layer proteins obtained from epidemic and hypervirulent *Clostridium difficile* strain. J Med Microbiol. 2011;60:1162–70.

31. Melo-Filho A, Souza M, Lyerly D, et al. Role of tumor necrosis factor and nitric oxide in the cytotoxic effects of *Clostridium difficile* toxin A and toxin B on macrophages. Toxicon. 1997;35:743–52.

32. Castiglione L, Keates AC, Wang CC, et al. *Clostridium difficile* toxin A stimulates macrophage-inflammatory protein-2 production in rat intestinal epithelial cells. J Immunol. 1998;160:6039–45.

33. Bianco M, Fedele G, Quattrini A, et al. Immunomodulatory activities of surface-layer proteins obtained from epidemic and hypervirulent *Clostridium difficile* strain. J Med Microbiol. 2011;60:1162–70.

34. Melo-Filho A, Souza M, Lyerly D, et al. Role of tumor necrosis factor and nitric oxide in the cytotoxic effects of *Clostridium difficile* toxin A and toxin B on macrophages. Toxicon. 1997;35:743–52.

35. Cunney R, Magee C, McNamara E, et al. *Clostridium difficile* toxin A and toxin B. Infect Immun. 1991;59:3659–66.

36. Castiglione L, Keates AC, Wang CC, et al. *Clostridium difficile* toxin A stimulates macrophage-inflammatory protein-2 production in rat intestinal epithelial cells. J Immunol. 1998;160:6039–45.

37. Bianco M, Fedele G, Quattrini A, et al. Immunomodulatory activities of surface-layer proteins obtained from epidemic and hypervirulent *Clostridium difficile* strain. J Med Microbiol. 2011;60:1162–70.

38. Melo-Filho A, Souza M, Lyerly D, et al. Role of tumor necrosis factor and nitric oxide in the cytotoxic effects of *Clostridium difficile* toxin A and toxin B on macrophages. Toxicon. 1997;35:743–52.

39. Cunney R, Magee C, McNamara E, et al. *Clostridium difficile* toxin A and toxin B. Infect Immun. 1991;59:3659–66.

40. Dobson G, Hickey C, Trinder J. *Clostridium difficile* toxin A causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Intensive Care Med. 2003;29:1030.

41. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–29.

42. Sakamoto Y, Mashiko K, Obata T, et al. Relationship between effect of polymyxin B-immobilized fiber and high-mobility group box 1 protein in septic shock patients. ASAIO J. 2007;53:324–8.

43. Sakamoto Y, Mashiko K, Obata T, et al. Effects of polymyxin B-immobilized fiber treatment on postoperative septic shock evaluated from various sepsis relation factors and various cytokines using multiple suppression array system. Jpn J Crit Endotoxiemia. 2010;1497–103.

44. Kimura Y, Sato K, Tokuda H, et al. Effects of combination therapy with direct hemoperfusion using polymyxin B-immobilized fiber and oral vancomycin on fulminant pseudomembranous colitis with septic shock. Dig Dis Sci. 2007;52:675–8.

45. Kimura Y, Sato K, Tokuda H, et al. Combination therapy with direct hemoperfusion using polymyxin B-immobilized fiber and oral vancomycin improves fulminant pseudomembranous colitis by reducing the elevated endogenous cannabinoids and inflammatory cytokines: report of a case. Hepato- Gastroenterology. 2008;55:956–8.

46. Esmon CT. Coagulation and inflammation. J Endotoxin Res. 2003;9(3):192–8.

47. Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas. 2004;47(6):305–14.

48. Shimizu S, Gabazza EC, Taguchi O, et al. Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am J Respir Crit Care Med. 2003;167:1416–26.

49. Suzuki K, Gabazza EC, Hayashi T, et al. Protective role of activated protein C in lung and airway remodeling. Crit Care Med. 2004;32 Suppl S:S262–S.